Literature DB >> 2740469

Plasma and CSF HVA before and after pharmacological treatment.

R Sharma1, J I Javaid, P Janicak, K Faull, J Comaty, J M Davis.   

Abstract

Plasma and cerebrospinal fluid (CSF) levels of the major dopamine metabolite homovanillic acid (HVA) were measured in psychiatric patients after an average washout period of 19 days, and again after 4 weeks of pharmacological treatment. Absolute values of plasma HVA did not correlate with absolute values of CSF HVA either at baseline or after treatment. However, changes in plasma HVA were highly correlated with changes in CSF HVA. Further, while baseline levels of plasma and CSF HVA were not significantly correlated with baseline clinical measures, clinical improvement was associated with decreases in both plasma and CSF HVA. This reached statistical significance for the plasma HVA level/clinical response relationship.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2740469     DOI: 10.1016/0165-1781(89)90201-1

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  Acute lithium administration selectively lowers tyrosine levels in serum and brain.

Authors:  Hewlet G McFarlane; John Steele; Keenan Vinion; Rodolfo Bongiovanni; Manda Double; George E Jaskiw
Journal:  Brain Res       Date:  2011-08-27       Impact factor: 3.252

2.  Clomipramine-induced serum prolactin as a marker for serotonin and dopamine turnover: results of an open label study.

Authors:  Joachim Cordes; Kai G Kahl; Christian Werner; Uwe Henning; Gunnar Regenbrecht; Rolf Larisch; Christian Schmidt-Kraepelin; Johanna Thünker; Marcus W Agelink; Stefan Löffler; Thomas Hohlfeld; Wolfgang Gaebel; Ansgar Klimke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-15       Impact factor: 5.270

3.  Variability of plasma homovanillic acid over 13 months in patients with schizophrenia; relationship with the clinical response and the Wisconsin card sort test.

Authors:  Mercedes Zumárraga; Miguel A González-Torres; Aurora Arrue; Ricardo Dávila; Wendy Dávila; Lucía Inchausti; Lucía Pérez-Cabeza; Aránzazu Fernández-Rivas; Sonia Bustamante; Nieves Basterreche; José Guimón
Journal:  Neurochem Res       Date:  2011-04-08       Impact factor: 3.996

4.  Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.

Authors:  A Wolkin; E Duncan; M Sanfilipo; S Wieland; T B Cooper; J Rotrosen
Journal:  J Neural Transm Gen Sect       Date:  1994

5.  The biochemical womb of schizophrenia: A review.

Authors:  N Gaur; S Gautam; M Gaur; P Sharma; G Dadheech; S Mishra
Journal:  Indian J Clin Biochem       Date:  2008-12-20

6.  Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity.

Authors:  Robert D Oades; Bernd Röpcke; Uwe Henning; Ansgard Klimke
Journal:  Behav Brain Funct       Date:  2005-08-09       Impact factor: 3.759

7.  Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia.

Authors:  Hikaru Hori; Reiji Yoshimura; Asuka Katsuki; Kiyokazu Atake; Ryohei Igata; Yuki Konishi; Hiroki Beppu; Hirotaka Tominaga
Journal:  Int J Mol Sci       Date:  2017-03-06       Impact factor: 5.923

8.  Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion.

Authors:  Tanja Veselinović; Ingo Vernaleken; Paul Cumming; Uwe Henning; Lina Winkler; Peter Kaleta; Michael Paulzen; Christian Luckhaus; Gerhard Gründer
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-27       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.